JP2017522043A5 - - Google Patents

Download PDF

Info

Publication number
JP2017522043A5
JP2017522043A5 JP2017510285A JP2017510285A JP2017522043A5 JP 2017522043 A5 JP2017522043 A5 JP 2017522043A5 JP 2017510285 A JP2017510285 A JP 2017510285A JP 2017510285 A JP2017510285 A JP 2017510285A JP 2017522043 A5 JP2017522043 A5 JP 2017522043A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017510285A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017522043A (ja
JP6449441B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2015/004424 external-priority patent/WO2015167293A1/en
Publication of JP2017522043A publication Critical patent/JP2017522043A/ja
Publication of JP2017522043A5 publication Critical patent/JP2017522043A5/ja
Application granted granted Critical
Publication of JP6449441B2 publication Critical patent/JP6449441B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017510285A 2014-04-30 2015-04-30 FcRn特異的ヒト抗体及びこれを含む自己免疫疾患治療用組成物 Active JP6449441B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461986742P 2014-04-30 2014-04-30
US61/986,742 2014-04-30
PCT/KR2015/004424 WO2015167293A1 (en) 2014-04-30 2015-04-30 Antibody binding to fcrn for treating autoimmune diseases

Publications (3)

Publication Number Publication Date
JP2017522043A JP2017522043A (ja) 2017-08-10
JP2017522043A5 true JP2017522043A5 (enExample) 2018-03-22
JP6449441B2 JP6449441B2 (ja) 2019-01-09

Family

ID=54358928

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017510285A Active JP6449441B2 (ja) 2014-04-30 2015-04-30 FcRn特異的ヒト抗体及びこれを含む自己免疫疾患治療用組成物

Country Status (21)

Country Link
US (6) US10544226B2 (enExample)
EP (2) EP3137504B1 (enExample)
JP (1) JP6449441B2 (enExample)
KR (2) KR101954906B1 (enExample)
CN (2) CN106459215B (enExample)
AU (2) AU2015253915B2 (enExample)
CA (2) CA2945086C (enExample)
DK (1) DK3137504T5 (enExample)
EA (1) EA038470B1 (enExample)
ES (1) ES2952583T3 (enExample)
FI (1) FI3137504T3 (enExample)
HU (1) HUE062403T2 (enExample)
IL (2) IL248159B (enExample)
MX (2) MX382284B (enExample)
NZ (2) NZ726089A (enExample)
PL (1) PL3137504T3 (enExample)
PT (1) PT3137504T (enExample)
RS (1) RS64542B1 (enExample)
SA (1) SA516380194B1 (enExample)
SG (1) SG11201608208VA (enExample)
WO (1) WO2015167293A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106957365B (zh) * 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb8及其应用
WO2017189556A1 (en) * 2016-04-25 2017-11-02 Syntimmune, Inc. Humanized affinity matured anti-fcrn antibodies
KR20240151878A (ko) * 2016-07-29 2024-10-18 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
US20180325931A1 (en) 2017-01-21 2018-11-15 Ningbo Zhiming Biotechnology Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
BR112019026694A2 (pt) * 2017-06-15 2020-06-23 UCB Biopharma SRL Método para o tratamento da trombocitopenia imune
WO2019118791A1 (en) 2017-12-13 2019-06-20 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
JOP20210013A1 (ar) 2018-07-20 2021-01-19 Momenta Pharmaceuticals Inc تركيبات جسم مضاد fcrn
BR112021007092A2 (pt) 2018-10-16 2021-08-03 UCB Biopharma SRL método para o tratamento de miastenia grave
SG11202104115SA (en) * 2018-11-06 2021-05-28 Immunovant Sciences Gmbh Methods of treating graves' ophthalmopathy using anti-fcrn antibodies
GB2589049C (en) * 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
TW202132346A (zh) * 2019-11-19 2021-09-01 瑞士商依牧諾萬科學有限公司 使用抗-fcrn抗體治療溫抗體型自體免疫性溶血性貧血之方法
TWI869542B (zh) * 2020-02-10 2025-01-11 大陸商北京拓界生物醫藥科技有限公司 抗FcRn抗體、其抗原結合片段及其醫藥用途
CN115776879A (zh) * 2020-06-29 2023-03-10 韩兀生物制药股份有限公司 抗fcrn抗体制剂
JP7765457B2 (ja) * 2020-08-06 2025-11-06 ステレクシス セラピューティクス,エルエルシー Il-8抗体及びその使用方法
CN113484526B (zh) * 2021-08-11 2024-08-23 上海迈晋生物医药科技有限公司 一种抗FcRn抗体或其抗原结合片段生物学活性的检测方法
JP7755725B2 (ja) * 2021-08-13 2025-10-16 ジャンスー バイオジェッテイ バイオテクノロジー カンパニー リミテッド Fcrnを特異的に認識する抗体およびその使用
WO2023091920A1 (en) * 2021-11-16 2023-05-25 The University Of Chicago Polypeptides for detection and treatment of coronavirus infection
CN114573698B (zh) * 2022-03-16 2023-01-06 沈阳三生制药有限责任公司 一种FcRn抗原结合蛋白及其制备方法和应用
KR20250018382A (ko) * 2022-05-30 2025-02-05 한올바이오파마주식회사 안정성이 향상된 항-FcRn 항체 또는 이의 항원 결합 단편
WO2023235679A1 (en) 2022-05-30 2023-12-07 Hanall Biopharma Co., Ltd. Anti-fcrn antibody or antigen binding fragment thereof with improved stability
TW202423965A (zh) * 2022-07-27 2024-06-16 比利時商艾伯霖克斯公司 與新生兒fc受體的特定表位結合之多肽
WO2024052358A1 (en) 2022-09-06 2024-03-14 Immunovant Sciences Gmbh Methods of treating chronic inflammatory demyelinating polyneuropathy using anti-fcrn antibodies
CA3266954A1 (en) 2022-09-06 2024-03-14 Immunovant Sciences Gmbh METHODS OF TREATMENT OF GRAVES DISEASE USING ANTI-FCRN ANTIBODIES
AU2024232611A1 (en) 2023-03-08 2025-10-16 Immunovant Sciences Gmbh High concentration protein formulations with polysorbate excipients and methods of making the same
AR133188A1 (es) 2023-07-05 2025-09-03 Ablynx Nv ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG
WO2025017368A1 (en) 2023-07-16 2025-01-23 argenx BV Methods of treating chronic inflammatory demyelinating polyneuropathy
WO2025093717A1 (en) 2023-10-31 2025-05-08 Immunovant Sciences Gmbh Methods of improving anti-fcrn therapies
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis
WO2025163617A1 (en) 2024-02-04 2025-08-07 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
CN119490588A (zh) * 2024-10-17 2025-02-21 广州康盛生物科技股份有限公司 一种抗人FcRn的VHH抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US7662928B2 (en) * 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
WO2005013912A2 (en) 2003-08-08 2005-02-17 The Research Foundation Of State University Of Newyork Anti-fcrn antibodies for treatment of auto/allo immune conditions
EP1879920A2 (en) 2005-04-29 2008-01-23 The Jackson Laboratory Fcrn antibodies and uses thereof
WO2007087289A2 (en) * 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatement of auto/allo immune conditions
KR101703299B1 (ko) 2007-06-01 2017-02-06 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
CN108467431A (zh) 2008-04-25 2018-08-31 戴埃克斯有限公司 针对fcrn的抗体及其用途
PH12013502378A1 (en) * 2011-06-02 2014-01-06 Dyax Corp Fc RECEPTOR BINDING PROTEINS
KR20130071961A (ko) * 2011-12-21 2013-07-01 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
PL2992012T3 (pl) 2013-04-29 2019-12-31 F. Hoffmann-La Roche Ag Zmodyfikowane ludzkie przeciwciała wiążące FcRn i sposoby ich zastosowania
KR101815265B1 (ko) * 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물

Similar Documents

Publication Publication Date Title
JP2017522043A5 (enExample)
JP7453206B2 (ja) 改良された血清アルブミン結合剤
JP2014526898A5 (enExample)
JP2013538057A5 (enExample)
FI3137504T3 (fi) Fcrn:ään sitoutuva vasta-aine autoimmuunisairauksien hoitamista varten
JP2018521638A5 (enExample)
JP2020525032A5 (enExample)
JP2018512138A5 (enExample)
JP2017522903A5 (enExample)
JP2018502561A5 (enExample)
RU2016100892A (ru) Антитела против tweakr и их применение
JP2017113028A5 (enExample)
HRP20170568T1 (hr) Protutijela anti-ox40 i postupci za njihovu uporabu
JP2018537421A5 (enExample)
JP2016507555A5 (enExample)
JP2016511277A5 (enExample)
JP2014511179A5 (enExample)
JP2014524733A5 (enExample)
JP2011514150A5 (enExample)
JP2018502060A5 (enExample)
JP2018535650A5 (enExample)
JP2017531427A5 (enExample)
JP2015517470A5 (enExample)
JP2012501670A5 (enExample)
JP2018527919A5 (enExample)